Idiopathic pulmonary fibrosis

Idiopathic pulmonary fibrosis (IPF) is a clinical syndrome and considered the most common and the most lethal form of pulmonary fibrosis corresponding to the histologic and imaging pattern of UIP. It is more common in middle age or elderly men and diagnosed by: 

  1. histological or imaging pattern of usual interstitial pneumonia (UIP) and
  2. absence of alternative causes such as drug toxicity, environmental exposure (e.g. asbestos) or collagen vascular disease (e.g. scleroderma, rheumatoid arthritis)

Epidemiology

It tends to be commoner in males with most cases presenting in those over 50 years of age.

Clinical presentation

Patients typically present with progressive dyspnea on exertion and chronic dry cough, finger clubbing, chest pain, fatigue, malaise, and weight loss. Pulmonary function test results may be normal in mild disease or shows restriction pattern (i.e. reduced vital capacity and total lung capacity but near normal residual volume). DLCO is commonly decreased even in with mild cases. 

Diagnostic criteria

Multidisciplinary approach in tertiary setting is strongly advised. Contributions from pulmonists, chest radiologists, and chest pathologist are crucial reaching the correct diagnosis of IPF. 

ATS/ERS (American Thoracic Society and European Respiratory Society) has developed major and minor criteria for the diagnosis of IPF in the absence of a surgical lung biopsy 5:

Major criteria
  • exclusion of other known causes of interstitial lung disease (e.g. toxic effects of certain drugs, environmental exposures, connective tissue diseases) abnormal results of pulmonary function studies, including evidence of restriction (reduced vital capacity, often with an increased FEV1/FVC ratio) and impaired gas exchange (increased PaO2, decreased PaO2 with rest or exercise, or decreased DlCO)
  • bibasilar reticular abnormalities with minimal ground-glass opacities at high-resolution CT: definite UIP pattern on HRCT chest 
  • transbronchial lung biopsy or bronchoalveolar lavage shows no features to support an alternative diagnosis
Minor criteria
  • age >50 years
  • insidious onset of otherwise unexplained dyspnea on exertion
  • duration of illness being over 3 months
  • bibasilar inspiratory crackles (dry or “Velcro” type)

Pathology

IPF as the name implies it is idiopathic however there is an association with concurrent or previous history of smoking in 60% of patients and genetic factors. Up to 5–20% of patients with IPF have a family history of ILD or pulmonary fibrosis. More recently it has been shown that fibroblasts in this process demonstrate neoplastic or neoproliferative characteristics 11

Genetics

The rs35705950 single-nucleotide polymorphism (SNP)—a promoter site of an airway mucin gene (MUC5B)—is strongly associated with IPF and familial pulmonary fibrosis and not seen in other secondary causes of lung fibrosis. Positive rs35705950 SNP in IPF patients is associated with slightly better prognosis and outcome. 

Histopathology

Histology shows UIP pattern which is characterized by spatial and temporal heterogeneity. One of the hall marks is the absence of inflammation.  Spatial heterogeneity denotes biopsy sample showing patchy lung involvement with normal lung interspace between diseased lung. Temporal heterogeneity denotes different stages of disease seen on a single specimen, including normal lung, interstitial fibrosis and fibroblastic foci 4.

Radiographic features

The CT imaging findings complement the histology. It is more correct to describe characteristic imaging pattern as UIP rather than IPF,  a terminology assigned for the idiopathic clinical syndrome of UIP.

A UIP-pattern of fibrosis is characterised by honeycombing cysts and reticular septal thickening with subpleural and posterior basal predominance. Traction bronchiectasis can also be observed, however, this is a general feature of fibrosis not specific to UIP-pattern 4. In a subgroup of patients the imaging finding of UIP overlap with NSIP and biopsy may be necessary to obtain the correct diagnosis.

Treatment and prognosis

The clinical course is that of gradual deterioration and the condition carries a rather poor prognosis with median survival ranging from 2.5 to 3.5 years from the time of diagnosis (at the time of initial writing) 2. Some reports have suggested a slowing of progression with treatment by pirfenidone or nintedanib 7-8.

Differential diagnosis

Consider pulmonary fibrosis due to a known cause, such as:

See also

Edit Article Share
URL of Article

Article Information:

rID: 16929
System: Chest
Section: Pathology
Tag: cases
Synonyms or Alternate Spellings:
  • Idiopathic pulmonary fibrosis (IPF)
  • IPF
  • Drag
    Case 1
    Drag here to reorder.
  • Drag
    Case 2
    Drag here to reorder.
  • Updating… Please wait.
    Loadinganimation

    Alert_accept

    Error Unable to process the form. Check for errors and try again.

    Alert_accept Thank you for updating your details.